January - February
phase II trial in U.S.
Clinical study of a drug called galantamine
hydrobromide for treatment
of CFIDS is beginning in the United States. The four-month trial is a placebo-controlled study and will
be conducted at 12 sites with a total of 140 participants.
The sites, with doctor and contact
- Oceanside, Calif.; Dr. T. Chippendale, North County Neurology Assoc.;
Tracy Sweet, 760/732-0557, ext. 7.
- Washington, D.C.; Dr. Gary Simon, George Washington University;
Barbara Lewis, 202/994-2417.
- Fort Lauderdale, Fla.; Dr. Y. Sherrer, Centre for Rheumatology,
Immunology and Arthritis; Karen Herr, 954/229-0524.
- Miami, Fla.; Dr. Nancy Klimas, VA Medical Center; Mack Smith, 305/324-3267.
- Lansing, Mich.; Dr. Robert Bielski, Institute for Health Studies;
Recruitment Center, 800/682-6663.
- Ridgewood, N.J.; Dr. Kenneth Levin, Neurology Group of Bergen Co.;
Joanne Blayman, 201/612-3089.
- New York, N.Y.; Dr. Alexander Mauskop, N.Y. Headache Center; Elizabeth
Van Hook, 212/794-3550.
- Cincinnati, Ohio; Dr. B. Corser, Community Research Management Associates;
Lisa Izzo, 513/721-3868.
- Portland, Ore.; Dr. W. Smith, Pacific Northwest Clinical Research;
Michelle Manhart, 503/293-5039.
- Harrisburg, Pa.; Dr. Nelson Gantz, Pinnacle Health at Polyclinic
Hosp.; Michele Marcus, 717/782-2986.
- Seattle, Wash.; Dr. P. Londborg, Seattle Clinical Research Center;
Recruitment Center, 206/292-2273.
- Madison, Wis.; Dr. Leslie Taylor, Dean Foundation for Health Research;
Lisa Jorgensen, 608/827-2340.
Recruitment ends in February. Patients
with a diagnosis of CFIDS
or fibromyalgia may be suitable. Entry criteria include: ages 18–65; no prescribed anti-depressants or
medication for CFIDS during the study; no other physical of psychiatric illness; no history of CFIDS in
excess of seven years.
The study involves: up to eight visits
to the clinic over a four-month
period; taking two tablets three times per day (this may be either the treatment or a placebo); completing
questionnaires, performing simple computer tests, and having a small blood sample taken at each visit.
The manufacturer, Shire Laboratories
of England, describes the drug
as a reversible cholinesterase inhibitor. According to Taber’s Cyclopedic Medical Dictionary,
cholinesterase is an enzyme that breaks down acetylcholine, which is believed to play a key role in the
transmission of nerve impulses at brain synapses and at nerve endings in muscles.